Compare Nu Holdings Ltd (NU) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs Pfizer Inc — how do they compare? Nu Holdings Ltd trades at $15.45 (market cap $74.30B), while Pfizer Inc trades at $27.83 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.1× Nu Holdings Ltd's market cap, and Pfizer Inc pays a 6.18% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nu Holdings Ltd for 53 Days and Pfizer Inc for 158 Days on average.
| NU | PFE | |
|---|---|---|
Market Cap | $74.30B | $158.56B |
Volume | 80,294,805 | 44,138,282 |
Sector | Financials | Health |
52-Week High | $18.76 | $29.02 |
52-Week Low | $11.60 | $23.67 |
Typical Hold Time | 53 Days | 158 Days |
Enterprise Value | $96.91B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU Holdings (NU) trades at $15.58, down 0.51% on the day, as the Brazilian digital bank navigates market volatility. The stock shows strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Technical indicators are mixed with a bullish moving average signal but overbought RSI conditions. Recent news highlights acquisition speculation and Goldman Sachs' bullish $19 price target.
NU presents a compelling growth story with expanding profitability and analyst support, though risks include credit concentration and acquisition uncertainty. The stock trades near consensus targets with 57% buy ratings, suggesting moderate upside potential if execution continues.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
